Evista (raloxifene) reduces the risk of MI and stroke in postmenopausal women

March 2002

A new analysis suggests that Evista (raloxifene) reduces the risk of MI and stroke in postmenopausal women.

This "selective estrogen" has some advantages for preventing or treating osteoporosis in postmenopausal women.

Both Evista and estrogen increase bone density.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

patients with EARLY rheumatoid arthritis should get more than just an NSAID
Smoking Cessation deaths in smokers taking Zyban (bupropion)
Cholesterol whether statins cause memory problems
Anticoagulants which antibiotics are safe to use in patients on warfarin
Anticoagulants Arixtra (fondaparinux sodium), the first in a new class of SYNTHETIC antithrombotics
teens abusing Coricidin HBP Cough and Cold tablets
Finally we have a NATIONAL poison hotline, 800-222-1222
Dermatology Sporanox (itraconazole) to PREVENT recurrent tinea versicolor
Dermatology Elidel, a new non-steroidal cream for atopic dermatitis
Women's Health Evista (raloxifene) reduces the risk of MI and stroke in postmenopausal women
Gastroenterology treat H. pylori before starting chronic NSAIDs
Gastroenterology Some patients with irritable bowel syndrome are begging the FDA to allow Lotronex (alosetron) back on the market
using cholinesterase inhibitors for patients with VASCULAR dementia
sudden "sleep attacks" in Parkinson's patients while driving
antipsychotics and metabolic effects
Renal & Urology Can patients with recurrent kidney stones take calcium